| 1 |
35358627 | Palbociclib in combination with sunitinib exerts a synergistic anti-cancer effect in patient-derived xenograft models of various human cancers types. | 2022 Jun 28 |
1 |
| 2 |
35500680 | Necroptosis modulation by cisplatin and sunitinib in hepatocellular carcinoma cell line. | 2022 Jul 15 |
1 |
| 3 |
32578660 | Local delivery of sunitinib and Ce6 via redox-responsive zwitterionic hydrogels effectively prevents osteosarcoma recurrence. | 2020 Aug 5 |
2 |
| 4 |
32814829 | Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma. | 2020 Sep |
2 |
| 5 |
28990511 | Sunitinib in the Treatment of Thyroid Cancer. | 2019 |
4 |
| 6 |
31025080 | Upregulation of phosphoinositide 3-kinase prevents sunitinib-induced cardiotoxicity in vitro and in vivo. | 2019 Jun |
2 |
| 7 |
28105557 | The anticancer drug sunitinib promotes autophagyand protects from neurotoxicity in an HIV-1 Tat model of neurodegeneration. | 2017 Apr |
1 |
| 8 |
28693255 | Sodium butyrate enhances the growth inhibitory effect of sunitinib in human renal cell carcinoma cells. | 2017 Jul |
4 |
| 9 |
28736633 | Biologics in gastrointestinal and pancreatic neuroendocrine tumors. | 2017 Jun |
2 |
| 10 |
27149458 | Recurrent Olfactory Neuroblastoma Treated With Cetuximab and Sunitinib: A Case Report. | 2016 May |
1 |
| 11 |
25376776 | The interplay of cyclic stretch and vascular endothelial growth factor in regulating the initial steps for angiogenesis. | 2015 Jan-Feb |
1 |
| 12 |
25637219 | AXL as a modulator of sunitinib response in glioblastoma cell lines. | 2015 Mar 1 |
2 |
| 13 |
25971960 | Receptor Tyrosine Kinase Expression Predicts Response to Sunitinib in Breast Cancer. | 2015 Dec |
1 |
| 14 |
26003083 | Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells. | 2015 May |
2 |
| 15 |
26291023 | Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. | 2015 Sep |
1 |
| 16 |
24045439 | Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy. | 2014 Apr |
4 |
| 17 |
24276455 | Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer. | 2014 Feb |
2 |
| 18 |
24424564 | Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study. | 2014 Dec |
1 |
| 19 |
24703573 | Activity of sunitinib in extraskeletal myxoid chondrosarcoma. | 2014 Jun |
1 |
| 20 |
24744988 | Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? | 2014 |
1 |
| 21 |
25085632 | Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. | 2014 Aug 1 |
4 |
| 22 |
25309777 | Molecular pathogenesis and targeted therapies in well-differentiated thyroid carcinoma. | 2014 Sep |
1 |
| 23 |
23454556 | Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. | 2013 Apr 5 |
1 |
| 24 |
23544171 | In Vitro and In Vivo Analysis of RTK Inhibitor Efficacy and Identification of Its Novel Targets in Glioblastomas. | 2013 Apr |
1 |
| 25 |
24061866 | Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis. | 2013 Dec |
1 |
| 26 |
30349606 | Current and Future Perspectives in Thyroid Carcinoma Treatment. | 2013 Mar |
1 |
| 27 |
21455800 | Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts. | 2012 Jun |
2 |
| 28 |
22080184 | A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. | 2012 Jun |
2 |
| 29 |
22191389 | Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells. | 2012 Feb |
2 |
| 30 |
22442268 | Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. | 2012 Jun |
5 |
| 31 |
22866542 | Structural and functional analysis of KIT gene encoding receptor tyrosine kinase and its interaction with sunitinib and HDAC inhibitors: an in silico approach. | 2012 Feb 1 |
1 |
| 32 |
23102636 | Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma. | 2012 Dec |
1 |
| 33 |
21242589 | Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. | 2011 Jul |
1 |
| 34 |
21325074 | Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. | 2011 Apr 1 |
3 |
| 35 |
21469976 | Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma. | 2011 May |
1 |
| 36 |
21725210 | Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation. | 2011 Sep 1 |
6 |
| 37 |
19649772 | Phase II study of sunitinib malate in head and neck squamous cell carcinoma. | 2010 Oct |
1 |
| 38 |
19900123 | Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management. | 2010 |
1 |
| 39 |
20629553 | Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer. | 2010 Sep |
10 |
| 40 |
20696054 | Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. | 2010 |
1 |
| 41 |
18534874 | Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. | 2009 Jul-Aug |
1 |
| 42 |
19017755 | Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. | 2009 Feb |
1 |
| 43 |
19453268 | Sunitinib in solid tumors. | 2009 Jun |
1 |
| 44 |
19468197 | Medullary thyroid cancer: molecular biology and novel molecular therapies. | 2009 |
1 |
| 45 |
19894779 | Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. | 2009 |
1 |
| 46 |
17505827 | A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. | 2008 Mar |
1 |
| 47 |
17945482 | Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. | 2008 Feb |
1 |
| 48 |
18418222 | Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. | 2008 Jun |
1 |
| 49 |
18537751 | Developments in targeted therapy of advanced gastrointestinal stromal tumors. | 2008 Jun |
1 |
| 50 |
17327610 | Sunitinib: from rational design to clinical efficacy. | 2007 Mar 1 |
1 |